Announcement on Obtaining Drug Registration Certificate for Shenpu Granules
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Obtaining Drug Registration Certificate for Shenpu Granules
Filed with SSE · · 3 pages · Chinese
Release
Jiangsu Kanion Pharmaceutical Co. Ltd. on 6ix
Earlier from Jiangsu Kanion Pharmaceutical
- Announcement on the Receipt of the Clinical Trial Approval Notice for KYS2301 Gel
- Announcement on Outgoing of Chairman
- Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License
- Announcement on Passive Increase in Shareholding Ratio of Controlling Shareholder Due to Repurchase and Cancellation of Restricted Stocks by the Company Touching an Integer Multiple of 1%
- Announcement on Implementing Repurchase and Cancellation of All Remaining Restricted Stocks under the 2022 Annual Restricted Stocks Incentive Plan
Later from Jiangsu Kanion Pharmaceutical
- Announcement on the Receipt of the Clinical Trial Approval Notice for Jianpi Shugan Guben Granules
- Announcement on the Receipt of the Clinical Trial Approval Notice for Jinzhen Oral Liquid with Increased Indications
- 2025 Semi-annual Report
- Announcement on Pledge of Some Shares Held by Shareholders with Over 5% Shares
- Announcement on Wholly-owned Subsidiary's Drug Additional Indication Obtaining Clinical Trial Approval Notice
Follow Jiangsu Kanion Pharmaceutical into a list and get an email when it puts out news.
Follow Jiangsu Kanion Pharmaceutical